GRT 6010

Drug Profile

GRT 6010

Alternative Names: GRT-6010

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Grunenthal
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Interstitial cystitis
  • Discontinued Neuropathic pain

Most Recent Events

  • 25 May 2017 Phase-II clinical trials in Interstitial cystitis in Poland (Intravesicular) (EudraCT2016-003940-35)
  • 01 Oct 2014 Grunenthal terminates phase II trial in Neuropathic pain in Germany, Poland, Hungary and United Kingdom (NCT01485094)
  • 01 Feb 2012 Phase-II clinical trials in Neuropathic pain in Germany (PO) (NCT01485094)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top